GlassScriptPhysician profile
Meaghan L Gift
NPI 1336532019
$3,409.79
in general payments reported to CMS, 2019-2025
34 companies · $697 in 2025
The $697 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $591 · 2023: $780 · 2024: $1,049 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,525.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $727.29 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $584.09 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $345.48 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $306.18 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $262.53 | 2022-2025 | |
| Lilly USA, LLC | $241.98 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Phathom Pharmaceuticals, INC. | $139.83 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $79.52 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $73.33 | 2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.21 | 2022-2023 | Tradjenta, Jardiance |
| Dexcom, INC. | $52.78 | 2021-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $47.68 | 2021 | |
| Abbvie INC. | $46.39 | 2022-2024 | |
| Boston Scientific Corporation | $43.07 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $37.89 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $36.45 | 2022 | |
| Vanda Pharmaceuticals INC. | $30.00 | 2024 | Fanapt, Hetlioz |
| Acadia Pharmaceuticals INC | $25.36 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.07 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $22.84 | 2023 | Fycompa |
| Xeris Pharmaceuticals, INC. | $21.13 | 2023 | Gvoke Hypopen |
| Alnylam Pharmaceuticals INC. | $20.87 | 2023 | Onpattro |
| Eisai INC. | $20.86 | 2024 | |
| Collegium Pharmaceutical, INC. | $19.90 | 2025 | Belbuca |
| Avion Pharmaceuticals | $18.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.90 | 2022 | |
| Astellas Pharma US INC | $16.88 | 2024 | Veozah |
| Azurity Pharmaceuticals, INC. | $16.81 | 2023 | Horizant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.06 | 2023 | Xifaxan |
| Lundbeck LLC | $14.63 | 2024 | Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.52 | 2024 | Caplyta |
| Sanofi-Aventis U.S. LLC | $14.31 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.35 | 2021 | |
| Inogen, INC. | $6.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meaghan Gift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.